Shares of Viking Therapeutics Inc. (VKTX) have surged approximately 20% within a week amid growing anticipation for the Phase 2 clinical trial results of its oral weight loss drug VK2735. Market analysts and investors are closely watching the upcoming data readout, with expectations centered on both efficacy and safety outcomes. A weight loss result near or above 9% at the 60-90 mg doses, coupled with a favorable safety profile, is considered a strong performance, especially when compared to Eli Lilly's (LLY) oral weight loss drug, which demonstrated a 12.4% weight loss over 72 weeks. Safety metrics, particularly the incidence of vomiting below 20%, are viewed as critical factors that could distinguish VK2735 from competitors. JP Morgan has also issued notes on VKTX, reflecting the heightened analyst focus. The trial's results are expected to be pivotal in determining the drug's market potential, with the industry awaiting confirmation that VK2735 can deliver substantial weight loss with better tolerability than existing treatments.